Having an article published proves what we did has relevance
Em meio a uma crise de dengue que já registrou mais de 217 mil casos nas primeiras quatro semanas de 2024, o Instituto Butantan recebeu a validação científica internacional de sua vacina, publicada no New England Journal of Medicine com eficácia de 79,6%. A conquista não é apenas técnica: representa a possibilidade de que um país produza, em solo próprio, uma resposta soberana a uma doença que há décadas assombra suas populações mais vulneráveis. A ciência, quando submetida ao escrutínio rigoroso dos pares, transforma esperança em evidência — e evidência, em política pública possível.
- O Brasil enfrenta uma explosão de dengue em 2024, com quase cinco vezes mais casos no início do ano do que no mesmo período anterior, pressionando um sistema de saúde já sobrecarregado.
- A única vacina disponível no SUS, a Qdenga, chega em doses insuficientes para cobrir apenas 3 milhões de pessoas, forçando o Ministério da Saúde a restringir a vacinação a adolescentes em cidades de alto risco.
- A vacina do Butantan, agora validada por um dos periódicos científicos mais exigentes do mundo, oferece dose única e produção nacional — vantagens concretas sobre a concorrente importada.
- A proteção de 79,6% se mostrou consistente em todas as faixas etárias e segura tanto para quem já teve dengue quanto para quem nunca foi infectado, superando uma limitação crítica de vacinas anteriores.
- O registro na Anvisa está previsto para setembro de 2024, mas o caminho regulatório ainda exige análises extensas — e cada semana de espera é medida em novos casos e hospitalizações.
Na véspera de fevereiro, o Instituto Butantan alcançou um marco que vai além dos laboratórios: sua vacina contra a dengue foi publicada no New England Journal of Medicine com eficácia validada de 79,6%. O processo de revisão por pares — descrito pelo infectologista Esper Kallás, diretor do instituto, como exaustivo e implacável nos detalhes — conferiu ao resultado o peso da credibilidade científica internacional. Para Kallás, a publicação é a prova de que o trabalho foi rigoroso e os dados, confiáveis.
A vacina se posiciona como alternativa direta à Qdenga, da farmacêutica japonesa Takeda, já distribuída pelo SUS desde fevereiro. As duas apresentam eficácia semelhante, mas a vacina brasileira leva vantagem em dois aspectos práticos: dose única, que dispensa o intervalo de três meses exigido pela concorrente, e produção nacional, que reduz custos e dependência de importação. Num país que receberá apenas 6 milhões de doses da Qdenga em 2024 — suficientes para imunizar 3 milhões de pessoas —, essas diferenças têm peso real.
O estudo acompanhou 16.235 voluntários entre 2 e 59 anos por dois anos. A proteção foi de 90% em adultos, 77,8% em adolescentes e 80,1% em crianças pequenas. Ao contrário da vacina da Sanofi, que não é recomendada para pessoas sem infecção prévia por risco de agravamento da doença, a vacina do Butantan demonstrou segurança em ambos os grupos — uma distinção clínica relevante. Os efeitos adversos foram majoritariamente leves, com eventos graves em menos de 0,1% dos vacinados, todos com recuperação completa.
A urgência do contexto é inegável: só em janeiro de 2024, o Brasil registrou mais de 217 mil casos de dengue, quase cinco vezes o volume do mesmo período do ano anterior. O pedido de registro à Anvisa está previsto para setembro, mas o instituto reconhece que o cronograma pode se estender. Enquanto o processo regulatório avança, a vacina permanece como uma promessa concreta — científica e soberana — diante de uma crise que não espera.
On the last day of January, the Instituto Butantan's dengue vaccine cleared a significant hurdle: peer review in the New England Journal of Medicine, one of the world's most rigorous scientific publications. The vaccine demonstrated 79.6% efficacy in preventing dengue infection, a finding that vindicated work the institute had announced more than a year earlier but which now carried the weight of international scientific scrutiny.
The peer-review process itself matters enormously. Before a study appears in a high-impact journal, other researchers examine the data with exacting precision, questioning methodology and assumptions down to the smallest detail. Esper Kallás, the infectologist who directs Butantan and led the study, described the process as grueling but essential—a validation that the work was rigorous and the findings reliable. "Having an article published in the New England Journal is proof that what we did has relevance and followed strict data analysis," he said. "Peer review is ultra-rigorous. They ask about the smallest details."
The efficacy rate of 79.6% places the Butantan vaccine on par with Qdenga, a competitor from Japan's Takeda pharmaceutical company that is already being distributed through Brazil's public health system starting in February. But the Butantan vaccine carries potential advantages: it requires only a single dose, whereas Qdenga requires two doses spaced three months apart. That single-dose design matters practically—it allows immunity to develop quickly without waiting for a full vaccination schedule to complete. The Brazilian vaccine would also cost less to produce, since it would be manufactured domestically rather than imported.
These advantages take on urgency against Brazil's current dengue crisis. In just the first four weeks of 2024, the country recorded more than 217,000 cases—nearly five times the roughly 45,000 cases reported in the same period the previous year. The Qdenga shortage underscores the problem: Brazil will receive only 6 million doses this year, enough to vaccinate just 3 million people. The Health Ministry has had to restrict vaccination to adolescents aged 10 to 14 living in cities with the highest dengue incidence. A second vaccine option would help ease that bottleneck.
The Butantan study tracked 16,235 volunteers aged 2 to 59 years over two years. Protection was consistent across age groups: 90% in adults aged 18 to 59, 77.8% in those aged 7 to 17, and 80.1% in children aged 2 to 6. The vaccine proved effective in people who had been infected with dengue before and in those with no prior exposure, though protection was stronger in the previously infected group (89.2% versus 73.6%). Critically, unlike Sanofi's earlier dengue vaccine—which is not recommended for people never previously infected because it can increase the risk of severe disease—the Butantan vaccine is safe for both groups.
Adverse reactions were mostly mild to moderate: injection-site pain and redness, headache, and fatigue. Serious adverse events linked to the vaccine occurred in fewer than 0.1% of vaccinated people, and all recovered completely. The vaccine targets all four dengue virus types using attenuated virus, but during the study period only dengue types 1 and 2 circulated in Brazil. This means researchers can confirm 89.5% efficacy against type 1 and 69.6% against type 2, but cannot yet fully assess protection against the other two strains.
Kallás said the institute is working toward submitting a registration application to Brazil's health regulator, Anvisa, by September 2024, though he acknowledged the timeline could shift if additional analyses prove necessary. The relationship with Anvisa has been strong, he noted, but the institute must follow standard regulatory procedures. The path forward depends on completing the full data analysis and dossier—work that remains substantial even with the peer-reviewed publication now in hand. If approved, the Butantan vaccine could begin addressing one of Brazil's most pressing public health challenges.
Notable Quotes
Having an article published in the New England Journal is proof that what we did has relevance and followed strict data analysis. Peer review is ultra-rigorous.— Esper Kallás, director of Instituto Butantan
The great advantage of a single-dose vaccine is that it induces rapid immunity, without needing to wait for the complete vaccination schedule to have the expected protection level.— Esper Kallás
The Hearth Conversation Another angle on the story
Why does it matter that this study was published in the New England Journal of Medicine rather than just announced by Butantan?
Because peer review is the scientific equivalent of a stress test. Other experts examine your data, your methods, your conclusions. If they find flaws, the paper doesn't get published. When it does get published in a top journal, it means the work survived that scrutiny.
The efficacy is 79.6%—is that good?
It's competitive. Qdenga is at 80.2%, so they're essentially equivalent. But the single-dose advantage is what sets Butantan apart. You get protection faster without waiting for a second injection months later.
Why is Brazil so desperate for another dengue vaccine?
Because they're receiving only 6 million Qdenga doses annually, which covers 3 million people. Brazil has over 217,000 dengue cases in just the first month of this year. The math doesn't work. They need more supply.
What's the risk in approving this vaccine quickly?
Kallás said they have to follow standard regulatory procedures. Rushing could mean missing something important. But the pressure is real—people are getting sick now.
Is this vaccine safe for everyone?
Unlike Sanofi's dengue vaccine, yes. It works safely in people who've never had dengue before. That's a significant advantage because it expands who can be vaccinated.
When will Brazilians actually be able to get this vaccine?
Not until Anvisa approves it, which Butantan hopes happens by September 2024. Even then, production and distribution take time. The study itself continues until June when all volunteers complete five years of follow-up.